KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash from Investing Activities: 2012-2024

Historic Cash from Investing Activities for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to $165.0 million.

  • Xenon Pharmaceuticals' Cash from Investing Activities rose 7637.15% to $38.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $253.8 million, marking a year-over-year increase of 246.46%. This contributed to the annual value of $165.0 million for FY2024, which is 248.13% up from last year.
  • According to the latest figures from FY2024, Xenon Pharmaceuticals' Cash from Investing Activities is $165.0 million, which was up 248.13% from -$111.4 million recorded in FY2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Cash from Investing Activities peaked at $165.0 million during FY2024, and registered a low of -$293.4 million during FY2022.
  • Over the past 3 years, Xenon Pharmaceuticals' median Cash from Investing Activities value was -$111.4 million (recorded in 2023), while the average stood at -$79.9 million.
  • In the last 5 years, Xenon Pharmaceuticals' Cash from Investing Activities tumbled by 1,366.77% in 2021 and then surged by 248.13% in 2024.
  • Xenon Pharmaceuticals' Cash from Investing Activities (Yearly) stood at -$16.8 million in 2020, then crashed by 1,366.77% to -$246.8 million in 2021, then dropped by 18.90% to -$293.4 million in 2022, then skyrocketed by 62.04% to -$111.4 million in 2023, then spiked by 248.13% to $165.0 million in 2024.